BSD  Home Page
Search:


 

Return to the Top

BSD Medical Corporation (NASDAQ:BSDM) develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy as provided by focused radio frequency and microwave energy. BSD Medical is also making major progress in the application of its technology for other therapies.

Microwave hyperthermia therapy has been shown to substantially improve local control of cancer, tumor response and survival rates when added to radiation treatments. In phase III clinical trials where hyperthermia was combined with radiation therapy, hyperthermia improved 2-year local control of melanoma from 28% to 46%, complete response for recurrent breast cancer from 38% to 60%, 2-year survival for glioblastoma (brain cancer) from 15% to 31% and complete response for advanced cervical cancer from 57% to 83%, as compared to the use of radiation therapy alone.
BSD Medical Corporation was the first company to obtain PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for a hyperthermia cancer therapy system and the first company to obtain Investigational Device Exemption (IDE) approval from the FDA for thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH). BSD has sold and manufactured over 200 hyperthermia systems installed throughout the world. Since its founding, BSD Medical has invested over $20 million in development of technology for hyperthermia treatment, and substantially greater funding has been provided for the clinical trials by the U.S. National Institutes of Health (NIH) and European governments.

BSD is also the developer of the microwave thermal therapy systems used by TherMatrx, Inc., a company dedicated to the treatment of symptoms associated with enlarged prostate, a health condition affecting half of men over age 50. BSD Medical is currently engaged in an earn-out that is projected to provide a cash return of approximately $30-40 million for the sales of its shares in TherMatrx, Inc.

BSD Medical has 9 U.S. patents, 3 foreign patents and 5 patent licenses covering its current applications and products. New technologies are also under development that may qualify for patent protection.

Four additional BSD patents that apply to the treatment of enlarged prostate (BPH), a urological disease, have been assigned to TherMatrx, Inc. BSD Medical’s prior licensee, Urologix, Inc. (NAS :ULGX), which has marketed under license to these patents, subsequently became a licensee to TherMatrx.

Over 1,000 researchers, consisting substantially of physicians and physicists, are members of world organizations dedicated exclusively to research in hyperthermic oncology. Three hyperthermia research organizations service North America, Europe and Asia.

In the opening address of the 2001 annual conference of the North American Hyperthermic Society (sponsored by the Radiological Society of North America), P. K. Sneed, M. D. (Univ. of California San Francisco) offered the following summary of completed Phase III randomized clinical trials involving combination ionizing radiation (RT) plus hyperthermia therapy (HT) vs. ionizing radiation treatments alone: “for melanoma (2-year local control 28% for RT vs. 46% for RT + HT), recurrent breast cancer (complete response rate 38% for RT vs. 60% for RT + HT), glioblastoma (2-year survival 15% for RT vs. 31% for RT + HT), and advanced cervical cancer (complete response rate 57% for RT vs. 83% for RT + HT).”

BSD Medical Corporation has developed the technology required to approach hyperthermia therapy through three techniques: superficial, interstitial and deep hyperthermia. These methods allow cancer to be treated virtually anywhere in the body.

Superficial hyperthermia systems are used to non-invasively treat tumors within a few centimeters of the surface of the body, typical in conditions of melanoma and recurrent breast cancer. Interstitial hyperthermia is primarily used to treat tumors in combination with popular interstitial and endocavitary ionizing radiation therapy (brachytherapy), using tiny microwave antennae inserted through the same catheters required to deliver radioactive seeds. This technique can be employed in treating prostate cancer, breast cancer, head and neck cancer and a variety of other cancer sites. Deep hyperthermia is used to non-invasively treat tumors deep within the body, including many problematic cancer sites located in the pelvis, abdomen and chest areas.

Development of the BSD-2000 has been a substantial effort involving the cooperative work of such American research institutions as Duke University, Northwestern University, University of Southern California, Stanford University, University of Utah and University of Washington St. Louis. Contributing
European research institutions included Daniel den Hoed Cancer Center of the Academisch Ziekenhuis (Rotterdam, Netherlands), Haukeland University Hospital (Bergen, Norway), Düsseldorf University Medical School, Tübingen University Medical School, Essen University Hospital, Charité Medical School of Humboldt University (Berlin), Luebeck University Medical School, Munich University Medical School Grosshadern, Interne Klinik Argirov of the Munich Comprehensive Cancer Center (all of Germany), University of Verona Medical Center (Italy), Graz University Medical School (Austria) and Kantonsspital Aarau (Switzerland).

Through research funded by the National Cancer Institute and supportive efforts by other research institutions, BSD Medical has been able to further enhance the BSD-2000. The BSD-2000/3D adds three-dimensional steering of deep focused energy, delivering even more precise heating to the tumor. As part of the international collaborative research efforts, sophisticated treatment planning software for the BSD-2000/3D has also been developed.

Both the BSD-2000 and BSD-2000/3D administer non-invasive treatment to deep tumors. As a further objective, MRI treatment monitoring has also been added. The BSD-2000/3D/MR provides magnetic resonance imaging (MRI) as an interface with the BSD-2000/3D. The development of MRI treatment monitoring has been a long-awaited breakthrough in hyperthermic oncology. Among many benefits, MRI treatment monitoring opens the way for the application of MRI monitored hyperthermia for better treatment of new cancer sites, using non-invasive imaging (including temperature monitoring) of tumors during therapy.

Return to the Top

Click on the date of the Financial Statement you wish to view. Each date is directly linked to the EDGAR Database located on the U.S. Securities and Exchange Commission server.

If you would like copies of older Financial Statements or have any specific questions, please send your request to investor@bsdmc.com.

Return to the Top

BSD Medical has 46 employees who provide a broad complement of management, technical, regulatory, sales, marketing, production and administrative skills. Several key employees, including a seasoned medical sales director and a senior engineer have joined the BSD to complement the company’s growth plans. The Board of Directors and selected critical employees are as follows:

Paul F. Turner, MSEE (Chairman/Senior VP/Chief Technology Officer) joined BSD Medical Corporation in 1978 after seven years as a respected developer of microwave communications systems for Sperry Univac (now L3 Communications). His experience with advanced military defense communication systems prepared him to lead the development of sophisticated phased array microwave technology at BSD Medical. Mr. Turner has led the design of microwave treatment systems for tumors, including the development of external phased array antenna technology to focus radiated microwave energy deep into the central area of the body to treat deep tumors. He has also integrated this novel technology with Magnetic Resonance Imaging (MRI) to non-invasively monitor treatments within the patient's body. He is also a member of the STM Professional Affairs Committee

Hyrum A. Mead, MBA (President/CEO) joined BSD and elected to the Board of Directors in 1999. Previously he served five years as Vice President Business Development for ZERO Enclosures, a leading manufacturer in the telecommunications, computer and aerospace enclosures industry. He also served seven years as President of Electro Controls, a manufacturer of computer controlled power systems. Mr. Mead began his career in marketing with IBM where he worked with the introduction of many new products. His career has focused on growing businesses and making them successful, including turnarounds.

Dr. Gerhard Sennewald (Director) was appointed to BSD's Board of Directors in 1994. He has been a key BSD European representative and distributor. Dr. Sennewald is President and Chief Executive Officer of Medizin-Technik GmbH of Munich, Germany.

Dr. Michael Nobel (Director) was appointed to the Board of Directors in 1998. Dr. Nobel is Chairman of the Board of the Nobel Family Society that provides Nobel Prizes, including the Nobel Peace Prize. He is Chairman of the American Non-Violence Project Inc., and has served as a consultant to Unesco in Paris and the United Nations Social Affairs Division in Geneva. Dr. Nobel participated in the introduction of magnetic resonance imaging as European Vice President for Fonar Corp. He is the CEO of the MRAB Group which provides diagnostic imaging services.

Douglas P. Boyd, PhD (Director) Dr. Boyd founded Imatron in 1983, a medical technology company that produces electron beam tomography ("EBT") scanners, and served in various capacities, including Chairman and CEO. Imatron was later acquired by General Electric. Dr. Boyd also helped found Invision Technologies Inc., a company engaged in airport explosives detection. He served on the Invision board until its acquisition by General Electric in December 2004.

Dr. Boyd currently serves as Chairman of the Board of XLR Medical, Inc., as CEO of TeleSecurity Sciences, Inc., as Managing Director of Imaging Technology Ventures, Inc., and on the Board of Directors of Imaging Technology Group, Inc., TechniScan, Inc. and HealthAddress, Inc. He is internationally known as an expert in radiology and computed tomography ("CT") imaging systems, and has pioneered the development of fan-beam CT scanners, Xenon detector arrays and EBT scanners. Dr. Boyd has been awarded 13 U.S. patents. He is an Adjunct Professor of Radiology at the University of California, San Francisco, has published more than 100 scientific papers and is a frequent speaker at universities and symposiums.

Steven G. Stewart (Director) CPA, served as Chief Financial Officer for Headwaters, Inc. (a New York Exchange Company) from July 1998 until October 2005 when he became the Treasurer. Previously, Mr. Stewart served as a business assurance partner for PricewaterhouseCoopers LLP (formerly Coopers & Lybrand LLP), and as an audit partner with Ernst & Young (formerly Arthur Young), including service as the Director of High Technology and Entrepreneurial Services for the Salt Lake City office.

Timothy C. McQuay (Director) Mr. McQuay most recently served for ten years as Managing Director Investment Banking at A. G. Edwards & Sons, Inc. where he specialized in Healthcare, including medical technology, biotechnology and specialty pharmaceuticals. He previously served as Partner and Managing Director Investment Banking at Crowell, Weedon & Company; as Vice President Corporate Development at Kerr Group, Inc.; as Managing Director Merchant Banking at Union Bank of California; as Senior Vice-President Corporate Finance at Wedbush Morgan Securities, and as Vice-President Brokerage Services at Alexander & Alexander, Inc. Mr. McQuay holds an AB in Economics from Princeton University and an MBA from UCLA.

Dixie Toolson Sells (VP Regulatory Affairs) joined BSD Medical in 1978 and has directed the company’s regulatory affairs since 1984. Her efforts were largely instrumental in preparing the documentation required for obtaining FDA approval for the BSD-500 and for the products sold to TherMatrx, Inc. She currently leads the project to obtain FDA approval for the BSD-2000 and FDA clearance for the MicroThermX® Microwave Ablation System. She also serves on the Board of Directors of the Intermountain Biomedical Association.

J. Richard Faux (Director of Operations) joined the company in 1981 and leads BSD’s FDA compliant and ISO-9000 certified manufacturing facility.

Dennis Bradley (Accountant / Secretary) joined BSD in 1985 and has managed the company’s financial records and SEC relations and filings since 1987.

Brian L. Ferrand (VP of Sales) Joined BSD in 2005 as Vice President of Sales. Previously Mr. Ferrand served as Vice President of Sales and as a corporate officer of Merit Medical Systems, Inc. (a company traded on NASDAQ) from 1993 until October 2004. Previously Mr. Ferrand served as Director of Sales from 1992 to 1993 and as a National Sales Manager from 1991-1992 for Merit Medical. Merit Medical Systems is a producer of medical products used in cardiology and radiology sold on a worldwide basis.

Richard A. White, MBA, (VP of Business Development) has been deeply involved in business development and growth since obtaining his degree in international business at The Garvin School of International Management "Thunderbird" in 1980. He has played a key role in the founding of new companies, has led a national sales organization selling large capital equipment in power control systems. He has served as International Sales Manager for Merit Medical Systems, a leading manufacturer and marketer of products used in diagnostic and interventional cardiology and radiology procedures.

Dr. Mark Hagmann (Senior Engineer) joined BSD in 2000. He holds an undergraduate degree in physics and a PhD in electrical engineering. He has occupied important posts in universities and as a Senior Staff Fellow for the National Institutes of Health. Having published well over 100 articles in peer-reviewed journals, his expertise includes hyperthermia, lasers, microwave sciences and biotechnology.



Return to the Top

Wm. V. Frankel & Co., Inc.
30 Montgomery Street
Jersey City, NJ 07302
Tel: (800) 631-3091
Fax: (201) 434-4877
Hill Thompson Magid & Company
15 Exchange Place, Suite 800
Jersey City, NJ 07302
Tel: (800) 450-2566
Fax: (561) 477-3499
Herzog, Heine, Geduld, Inc.
525 Washington Boulevard
Jersey City, NJ 07310-1690
Tel: 800.756.1811
Fax:: 201.418.5006
www.herzog.com
M. H.. Meyerson & Co.
525 Washington Blvd.
Jersey City, NJ 07310
Tel: (800) 888-
Fax: (201) 459-0431
www.mhmeyerson.com
Paragon Capital Corporation
7 Hanover Square, 2nd Floor
New York, NY 10004
Tel: (800) 521-887
Fax: (561) 394-4580
Sharpe Capital Incorporated
120 Broadway
New York, NY 10271
Tel: (800) 355-5781
Fax: (212) 267-4217
Wilson-Davis
& Company

39 West Market
Salt Lake City, UT 84101
Tel: (800) 453-5735
Fax: (801) 578-2823
Wien Securities Corporation
5550 Glades Road, Suite 304
Boca Raton, FL 33431
Tel: (800) 898-2777
Fax: (561) 361-0780
Knight Equity Markets, L.P.
545 Washington Blvd.
Jersey City, New Jersey 07310
Telephone: 212.336.8690
Fax: 201.557.6853
Toll Free: 800.544.7508
Archipelago Trading Services, Inc.
2300 Maitland Center Parkway
Suite 317
Maitland, FL 32751
407-599-9900
www.archipelago.com
Citigroup Global Markets, Inc.
388 Greenwich St
New York, NY 10013
Phone: 212-816-6000
Fax: 212-793-9086
UBS Capital Markets, L.P.
111 Pavonia Ave. East
Jersey City, NJ 07310
Phone: 201-963-9100
Fax: 201-656-2411
Toll Free: 800-543-7995
Fulcrum Global Partners, LLC
New York (Headquarters)
535 Madison Avenue
New York, NY 10022
(212) 803-9000
Toll Free (866) 803-9001
   
Return to the Top


BSD Medical Corporation (“BSD”) is committed to the highest standards of legal and ethical business conduct. This Code of Business Conduct and Ethics summarizes the legal, ethical and regulatory standards that BSD Medical Corporation must follow and is a reminder to our directors, officers and employees, of the seriousness of that commitment. Compliance with this Code and high standards of business conduct is mandatory for every BSD employee.

Introduction
This Code is not intended to be a comprehensive guide to all of our policies or to all your responsibilities under law or regulation. It provides general parameters to help you resolve the ethical and legal issues you encounter in conducting our business. Think of this Code as a guideline, or a minimum requirement, that must always be followed. If you have any questions about anything in the Code or appropriate actions in light of the Code, you may contact the Ethics Officer, Ray Lauritzen, or the Chair of the Audit Committee who is Dr. Gerhard Sennewald.

We expect each of our directors, officers and employees to read and become familiar with the ethical standards described in this Code and to affirm your agreement to adhere to these standards by signing the Compliance Certificate that appears at the end of this Code. Violations of the law, our corporate policies, or this Code may lead to disciplinary action, including dismissal.

I. We Insist on Honest and Ethical Conduct By All of Our Directors, Officers, Employees and Other Representatives
We place the highest value on the integrity of our directors, our officers and our employees and demand this level of integrity in all our dealings. We insist on not only ethical dealings with others, but on the ethical handling of actual or apparent conflicts of interest between personal and professional relationships.

Fair Dealing
Directors, officers and employees are required to deal honestly and fairly with our customers, suppliers, competitors and other third parties. In our dealings with customers and suppliers, we:

  • prohibit our directors, officers and employees from accepting any bribe, kickback or improper payment from anyone;
  • prohibit gifts or favors of more than nominal value to or from our customers or suppliers;
  • limit marketing and client entertainment expenditures to those that are necessary, prudent, job-related and consistent with our policies;
  • require clear and precise communication in our contracts, our advertising, our literature, and our other public statements and seek to eliminate misstatement of fact or misleading impressions;
  • protect all proprietary data our customers or suppliers provide to us as reflected in our agreements with them;
  • be a consultant to, or a director, officer or employee of, or otherwise operate an outside business that:
  • markets products or services in competition with our current or potential products and services;
  • supplies products or services to BSD; or
  • purchases products or services from BSD;
  • have any financial interest, including significant stock ownership, in any entity with which we do business that might create or give the appearance of a conflict of interest;
  • seek or accept any personal loan or services from any entity with which we do business, except from financial institutions or service providers offering similar loans or services to third parties under similar terms in the ordinary course of their respective businesses;
  • accept any personal loan or guarantee of obligations from BSD, except to the extent such arrangements are legally permissible; or
  • conduct business on behalf of BSD with immediate family members, which include spouses, children, parents, siblings and persons sharing the same home whether or not legal relatives.
  • Not discuss confidential information with or in the presence of any unauthorized persons, including family members and friends;
  • Use confidential information only for our legitimate business purposes and not for personal gain;
  • Not disclose confidential information to third parties.
  • not make false or misleading entries in our books and records for any reason;
  • not condone any undisclosed or unrecorded bank accounts or assets established for any purpose;
  • comply with generally accepted accounting principles at all times;
  • notify our Accountant if there is an unreported transaction;
  • maintain a system of internal accounting controls that will provide reasonable assurances to management that all transactions are properly recorded;
  • maintain books and records that accurately and fairly reflect our transactions;
  • prohibit the establishment of any undisclosed or unrecorded funds or assets;
  • maintain a system of internal controls that will provide reasonable assurances to our management that material information about BSD is made known to management, particularly during the periods in which our periodic reports are being prepared;
  • present information in a clear and orderly manner and avoid the use of unnecessary legal and financial language in our periodic reports; and


III. We Comply With all Laws, Rules and Regulations
We will comply with all laws and governmental regulations that are applicable to our activities, and expect all our directors, officers and employees to obey the law. Specifically, we are committed to:

  • maintaining a safe and healthy work environment;
  • promoting a workplace that is free from discrimination or harassment based on race, color, religion, sex, age, national origin, disability or other factors that are unrelated to the Company’s business interests;
  • supporting fair competition and laws prohibiting restraints of trade and other unfair trade practices;
  • conducting our activities in full compliance with all applicable environmental laws;
  • keeping the political activities of our directors, officers and employees separate from our business;
  • prohibiting any illegal payments, gifts, or gratuities to any government officials or political party;
  • prohibiting the unauthorized use, reproduction, or distribution of any third party’s trade secrets, copyrighted information or confidential information;
  • complying with all applicable state and federal securities laws.

REPORTING AND EFFECT OF VIOLATIONS
Compliance with this code of conduct is, first and foremost, the individual responsibility of every director, officer and employee. We attempt to foster a work environment in which ethical issues and concerns may be raised and discussed with supervisors or with others without the fear of retribution. It is our responsibility to provide a system of reporting and access when you wish to report a suspected violation, or to seek counseling, and the normal chain of command cannot, for whatever reason, be used.

We will not allow any retaliation against a director, officer or employee who acts in good faith in reporting any violation.

Our Ethics Officer will investigate any reported violations and will determine an appropriate response, including corrective action and preventative measures, involving the Chair of the Audit Committee or Chief Executive Officer when required. All reports will be treated confidentially to every extent possible.

Return to the Top



One committee of the board of directors will be known as the audit committee, comprising at least two members. A majority of the members of the audit committee shall be independent directors.

The primary function of the audit committee is to assist the board in fulfilling its oversight responsibilities by reviewing the financial information that will be provided to the shareholders and others, the systems of internal controls management and the board of directors have established and all audit processes.

  1. The audit committee provides open avenues of communication with the independent accountant and the board of directors.

  2. The audit committee must report committee actions to the full board of directors and may make appropriate recommendations.

  3. The audit committee has the power to conduct or authorize investigations into matters within the committee's scope of responsibilities. The committee is authorized to retain independent counsel, accountants or others it needs to assist in an investigation.

  4. The audit committee will meet at least one time each year, more frequently if circumstances make that preferable. The audit committee chairman has the power to call an audit committee meeting whenever he or she thinks there is a need.

    An audit committee member should not vote on any matter in which he or she is not independent. The audit committee may ask members of management or others to attend the meeting and is authorized to receive all pertinent information from management.

  5. The audit committee will do whatever else the law, the company's charter or bylaws or the board of directors require.
  1. The audit committee will select the independent accountants for company audits. The committee's selection is subject to approval by the full board of directors. The audit committee also will review and set any fees paid to the independent accountants and review and approve dismissal of the independent accountants.

  2. The audit committee will confirm and assure the independence of the independent accountant, including a review of consulting services provided by the independent accountant and the fees paid for them.

  3. The audit committee will consider, in consultation with the independent accountant the audit scope and procedural plans made by the independent accountant.

  4. The audit committee will listen to management and the primary independent auditor if either thinks there might be a need to engage additional auditors. The audit committee will decide whether to engage an additional firm and, if so, which one.
  1. The audit committee will ascertain that the independent accountant views the board of directors as its client, that it will be available to the full board of directors at least annually and that it will provide the committee with a timely analysis of significant financial reporting issues.

  2. The audit committee will ask management and the independent accountant about significant risks and exposures and will assess management's steps to minimize them.

  3. The audit committee will review the following with the independent account:

    1. The adequacy of the company's internal controls, including computerized information system controls and security.

    2. Any significant findings and recommendations made by the independent accountant, together with management's responses to them.

  4. Shortly after the annual examination is completed, the audit committee will review the following with management and the independent accountant:

    1. The company's annual financial statements and related footnotes.

    2. The independent accountant's audit of and report on the financial statements.

    3. The auditor's qualitative judgments about the appropriateness, not just the acceptability, of accounting principles and financial disclosures and how aggressive (or conservative) the accounting principles and underlying estimates are.

    4. Any serious difficulties or disputes with management encountered during the course of the audit.

    5. Anything else about the audit procedures or findings that GAAS requires the auditors to discuss with the committee.

  5. The audit committee will review annual filings with the SEC and other published documents containing the company's financial statements and will consider whether the information in the filings is consistent with the information in the financial statements.

  6. The audit committee will review the interim financial reports with management and the independent accountant before those interim reports are released to the public or filed with the SEC or other regulators.

  7. The audit committee will prepare a letter for inclusion in the annual report that describes the committee's composition and responsibilities and how the responsibilities were fulfilled.
  1. Review and update the audit committee's charter annually.
  2. Review, with the independent accountant, the results of their examination of compliance with the company's code of conduct.
  3. Review legal and regulatory matters that may have a material effect on the organization's financial statements, compliance policies and programs and reports from regulators.
  4. Meet with the independent accountant and management in separate executive sessions to discuss any matters the audit committee or these groups believe should be discussed privately with the audit committee.

Return to the Top


Certain statements in the web site that relate to the future performance of BSD Medical Corporation or therapies performed on our equipment are "forward-looking" and are subject to risks and uncertainties inherent in our business that could cause actual results to differ materially from the statements. BSD Medical Corp. does not undertake responsibility to update such forward-looking statements. A detailed discussion of risks and uncertainties may be found in our Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Our recent SEC filings are available from this web site. BSD Medical Corporation is not responsible for nor do we endorse claims made on links included on our website.

Return to the Top


Contact us by email.

Return to the Top

Email Us
Terms of Use | Privacy Policy

Copyright © 2005 BSD Medical Corporation. All rights reserved.

Copyright © 2005 BSD Medical Corporation. All rights reserved.